Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading InspireMD’s dense filings can feel like a clinical trial of patience. Hundreds of pages track MicroNet-covered stent efficacy, FDA milestones and global trial costs—details that drive the share price but hide in footnotes.
Our platform turns that complexity into clarity. Whether you need the full InspireMD annual report 10-K simplified or the latest InspireMD quarterly earnings report 10-Q filing, Stock Titan’s AI pinpoints R&D spend, cash runway and pivotal trial updates in seconds. Real-time alerts surface every InspireMD insider trading Form 4 transactions notice, so you never miss executive stock moves.
Here’s what you can uncover today:
- Form 4 dashboards for InspireMD executive stock transactions Form 4 with real-time push.
- Instant summaries that answer “What changed in this 10-Q?” for busy clinicians and fund managers.
- 8-K trackers that flag device-approval news—InspireMD 8-K material events explained.
- Proxy insights that decode InspireMD proxy statement executive compensation versus peer med-tech firms.
No more line-by-line reading to find trial enrollment numbers or manufacturing cost shifts. Our expert layer explains ratios, spotlights risk wording and links related exhibits, making understanding InspireMD SEC documents with AI straightforward.
Save hours, spot inflection points earlier and answer questions like “Is management buying shares?” or “How much was spent on CGuard’s FDA study?” with confidence. Every filing, from the smallest 3-page 8-K to the exhaustive 300-page 10-K, is updated the moment it hits EDGAR—so your analysis stays ahead of the next catheter deployment.
Rosalind Advisors, Inc. and affiliated funds disclose aggregate beneficial ownership of 10,987,104 shares of InspireMD, Inc., equal to 9.9% of the 41,720,662 shares used for the calculation. The reported position combines 3,905,743 currently outstanding common shares and 7,081,361 shares issuable upon exercise of warrants as reflected on the cover pages.
The filing notes that the warrants include blocker provisions preventing exercise to the extent such exercise would raise beneficial ownership above 9.99%, so the actual exercisable shares are limited. The Schedule 13G/A is certified and signed by the reporting persons on 08/11/2025.
Rosalind Advisors and affiliated funds report shared beneficial ownership in InspireMD (NSPR), including common shares and warrants that together total 10,987,104 securities representing 9.4% of the class as stated on the cover page. The holding is shown as 3,905,743 common shares plus 7,081,361 shares issuable on warrants for the Advisor group, while Rosalind Master Fund L.P. reports 3,508,336 common and 5,977,361 warrant-issuable shares, and Rosalind Opportunities Fund I L.P. reports 397,407 common and 1,104,000 warrant-issuable shares. The filing notes that blocker provisions limit exercise of some warrants, so the actual exercisable ownership is lower than the raw totals. The Advisor and certain principals disclaim beneficial ownership of shares held by advised funds.
Rosalind Advisors, related funds and principals report material holdings in InspireMD (NSPR). The filing shows aggregate beneficial positions reported as 10,987,104 shares for several Reporting Persons, which the filing presents as approximately 9.4% of the class based on the S-3 share count and other per-entity percentages (Rosalind Master Fund L.P. 9.485,697 shares / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407 shares / 0.9%).
The reported totals include both currently outstanding common shares and shares issuable upon exercise of warrants (for example, Rosalind Advisors reports 3,905,743 common shares plus 7,081,361 shares issuable on warrants). The filing also discloses blocker provisions that prevent exercise of warrants to the extent doing so would push beneficial ownership above 9.99%, so the practical exercisable interest is lower than the raw issuable amount. The filing includes a certification that the holdings are held in the ordinary course of business and not for the purpose of changing control.
InspireMD, Inc. filed an 8-K dated August 5, 2025 reporting that it issued a press release with financial and operating results for the three and six months ended June 30, 2025 (Item 2.02) and made an updated investor presentation available (Item 7.01).
The filing states the press release is attached as Exhibit 99.1 and the investor presentation as Exhibit 99.2, and that both are furnished (not "filed") under General Instruction B.2. The presentation is available on the company website at https://www.inspiremd.com/en/investors/. This 8-K does not include the underlying financial figures; readers must consult the attached exhibits for results.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
